IFM Investors Pty Ltd Acquires 2,523 Shares of Humana Inc. (NYSE:HUM)

IFM Investors Pty Ltd lifted its stake in Humana Inc. (NYSE:HUM - Free Report) by 11.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 25,370 shares of the insurance provider's stock after buying an additional 2,523 shares during the period. IFM Investors Pty Ltd's holdings in Humana were worth $6,713,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. denkapparat Operations GmbH bought a new position in shares of Humana during the 4th quarter worth approximately $323,000. Allstate Corp bought a new position in Humana in the 4th quarter worth approximately $905,000. Deutsche Bank AG raised its holdings in Humana by 18.2% during the 4th quarter. Deutsche Bank AG now owns 631,371 shares of the insurance provider's stock worth $160,185,000 after purchasing an additional 97,071 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in Humana in the first quarter valued at about $1,309,000. Finally, Fred Alger Management LLC bought a new stake in shares of Humana in the 4th quarter valued at $451,000. 92.38% of the stock is owned by institutional investors.

Humana Price Performance

Shares of HUM stock traded down $5.22 on Friday, reaching $238.58. The company had a trading volume of 960,833 shares, compared to its average volume of 1,817,763. The stock has a market capitalization of $28.79 billion, a PE ratio of 16.87, a price-to-earnings-growth ratio of 1.81 and a beta of 0.44. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.71. Humana Inc. has a one year low of $212.45 and a one year high of $406.46. The business's 50-day moving average is $240.29 and its 200 day moving average is $258.86.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, beating the consensus estimate of $10.07 by $1.51. The business had revenue of $32.11 billion during the quarter, compared to the consensus estimate of $32 billion. Humana had a net margin of 1.42% and a return on equity of 14.47%. The firm's revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $7.23 EPS. Equities research analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a $0.885 dividend. The ex-dividend date is Friday, June 27th. This represents a $3.54 annualized dividend and a yield of 1.48%. Humana's dividend payout ratio is presently 25.04%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Mizuho increased their price objective on shares of Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Truist Financial set a $280.00 price target on Humana and gave the company a "hold" rating in a research note on Tuesday, June 17th. Oppenheimer lifted their price target on Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a report on Thursday, May 1st. Barclays set a $268.00 price objective on shares of Humana and gave the stock an "equal weight" rating in a research report on Thursday, June 12th. Finally, Bank of America reduced their price objective on Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a report on Tuesday, June 17th. Sixteen investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $280.76.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.